Poster
T-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DE-02; GOG-3122/ENGOT-en30)
Cara Mathews
Poster
R-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
Biomarker analysis of cadherin 6 (CHD6) and folate receptor alpha (FRα) expression, and raludotatug deruxtecan (R-DXd) antitumor activity by FRα status, in patients with platinum-resistant ovarian cancer from REJOICE-Ovarian01 and a first-in-human phase 1 study of R-DXd
Kathleen Moore
Poster
R-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
Evaluating treatment patterns and outcomes of patients with platinum resistant ovarian cancer: Results of a real-world cohort in the United States
Ritu Salani